|

Lutathera Clinical Trials

2 actively recruiting trials across 1 location

Also known as: (Lu 177)-N-[(4,7,10-Tricarboxymethyl-1,4,7,10- tetraazacyclododec-1-yl) acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-Lcysteinyl-L-threonine-cyclic (2-7) disulfide., 177 Lu-DOTA-octreotate, lutetium Lu 177 dotatate

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • Stanford University1
  • Institut du Cancer de Montpellier - Val d'Aurelle1

Indications

  • Cancer2
  • Progressive Disease1
  • Intestinal Well Differentiated Endocrine Tumor1
  • Gastroenteropancreatic Neuroendocrine Tumor1
  • Neuroendocrine Tumors1

Other1 trial

Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET
Phase 2

Stanford, California1 trial

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Stanford Cancer Institute Palo Alto

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.